RFK Jr.’s vaccine panel endorsed Merck’s RSV shot for babies, easing fears that his stance might delay rollout.

Merck's Enflonsia vaccine for respiratory syncytial virus won approval from the Centers for Disease Control and Prevention's ...

A CDC advisory panel on Thursday voted 5-2 to recommend the use of a new preventative RSV therapy in babies, Merck’s ...

Kennedy’s controversial panel overhaul met its first test. The result? A major win for public health ahead of RSV season.

The FDA delivered two notable approvals for RSV immunization, UroGen overcame a negative advisory committee vote to secure an ...

A group of outside advisers to the US Centers for Disease Control and Prevention voted 5-2 to recommend use of a new shot that can protect babies from respiratory syncytial virus, adding an additional ...

The votes in favor of Merck’s shot are a sigh of relief after Kennedy gutted the panel and tapped replacements, some of whom are well-known vaccine critics.

The United States could soon have another tool in the fight against respiratory syncytial virus, an illness that’s the No. 1 ...

The CDC’s Advisory Committee on Immunization Practices (ACIP) has blessed Merck’s new respiratory syncytial virus (RSV) shot ...

The simplicity of Merck's monoclonal antibody for RSV in infants could be a plus in its competition with AstraZeneca's existing treatment.

Merck said on Thursday its experimental antibody therapy, clesrovimab, demonstrated a 60.4% effectiveness in reducing some types of respiratory syncytial virus (RSV)-associated infections in infants.